drugset / Trial / NCT02095717

Multicenter Study Comparing Taxotere Plus Curcumin Versus Taxotere Plus Placebo Combination in First-line Treatment of Prostate Cancer Metastatic Castration Resistant (CURTAXEL)

NCT02095717

Phase 2 Terminated 50 enrolled Centre Jean Perrin
RandomizedParallel-groupTriple-blindTreatment

Summary

Multicenter randomized phase II study, double-blind, comparing Taxotere plus curcumin versus Taxotere plus placebo combination in first-line treatment of prostate cancer metastatic castration resistant. Assess time to progression (time to progression) of metastatic disease (from first day of treatment in the trial).

Timeline

Start
2014-03
Primary completion
2018-04
Completion
2018-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Curcumin Small molecule
Background Docetaxel Small molecule